About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

 
Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.

Spotlight

Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. More >

News & Events

   
Apr 30, 2015 MannKind Corporation to Hold 2015 First Quarter Financial Results Conference Call... More >
Apr 27, 2015 MannKind to Manufacture 12 Unit Cartridge Strength of AFREZZA(R) Following FDA Approval More >
Feb 24, 2015 MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results More >